![\"EBMH-Twitter-E-Card-B](\"https:\/\/blogs.bmj.com\/ebmh\/files\/2014\/10\/EBMH-Twitter-E-Card-B-big-300x212.jpg\")
<\/p>\n<\/p>\n
<\/p>\n
<\/p>\n
It will be on Friday 17th October at 3pm BST<\/strong>,\u00a0and it would be great if you could join.<\/p>\n Follow us on @EBMentalHealth<\/a> and use #EBMHchat to join in.<\/strong><\/p>\n A significant number of patients with schizophrenia do not respond adequately to an initial antipsychotic trial. What to do next? In case of treatment resistance, two strategies that are often used in clinical routine care contain dose increase of the current administered antipsychotic drug (dose escalation, high-dose treatment) and switch to another, new antipsychotic. According to available evidence, what approach should be preferred?\u00a0Is it true that, after treatment failure with at least two different antipsychotic drugs, a monotherapy with clozapine is considered to be the treatment option of first choice? Which is the\u00a0evidence in favour of\u00a0combination treatment of two antipsychotics?\u00a0What about augmentation of antipsychotics with other pharamcological agents?<\/p>\n These are some of the main questions that clinicians and patients face daily in clinical practice and these are the questions we will specifically address and answer during the tweet chat.<\/strong><\/em><\/p>\n The chat topic will be based on \u00a0review article published in May 2014 on Evidence Based Mental Health (http:\/\/ebmh.bmj.com\/). Here is the link:\u00a0http:\/\/ebmh.bmj.com\/content\/17\/2\/33.full<\/a>\u00a0or you can download the PDF of the paper, here:\u00a0Dold & Leucht, 2014_EBMH_Pharmacotherapy of treatment-resistant schizophrenia_a clinical perspective<\/a>.<\/p>\n If you would like to pre-submit a question for Stefan and EBMH for the tweet chat, do send it by either direct messaging @EBMentalHealth<\/a> using #EBMHchat on Twitter or on the EBMH Facebook page: \/Evidence.Based.Mental.Health<\/a>.<\/p>\n When it comes to the tweet chat, we suggest you use tchat.io<\/a>. This is a specific site used for tweet chats as it cuts out all the other distractions on Twitter. Log into tchat.io<\/a> using your Twitter details, then type #EBMHchat into the search bar. This pulls up all the tweets using the hashtag. You can tweet from here and it will automatically add the correct hashtag at the end of each tweet for those overexcited tweeps!<\/p>\n You can otherwise tweet using twitter, but you need to make sure you add the hashtag to each tweet otherwise we won\u2019t see it.<\/p>\n @EBMentalHealth<\/a> […]<\/p>\n![\"twitter](\"https:\/\/blogs.bmj.com\/ebmh\/files\/2014\/08\/twitter-sketch-icons.jpg\"){kind=icon}
<\/a>We very much enjoyed holding our first tweet chat a couple of weeks ago, so we have a date for the\u00a0next one!<\/p>\nChat topic:<\/h2>\n
<\/a>Pharmacotherapy of treatment-resistant schizophrenia: evidence base and clinical challenges
\n<\/b>Invited guest author: Stefan Leucht, Professor of Psychiatry and Vice chairman at the Department of Psychiatry and Psychotherapy TU-M\u00fcnchen & Honorary Professor of Evidence-based Psychopharmacology, University of Aarhus.<\/p>\nSupporting material:<\/h2>\n
Participating in the tweet chat: the mechanics<\/h2>\n
To join in you will need to have a Twitter account. To sign up to Twitter,\u00a0click here<\/a>\u00a0(it doesn\u2019t take long and make sure you follow us!).<\/p>\nEBMH chat representatives:<\/h2>\n
<\/a> \u2013 will be looked after by EBMH Associate Editor and chat host, Michael Ostacher
\n@StefanLeucht<\/span><\/a>\u00a0\u2013 is our guest author and EBMH Associate Editor, Stefan Leucht
\n@And_Cipriani<\/a> \u2013 EBMH Editor and chat facilitator, Andrea Cipriani
\n@MillwardHolly<\/a> \u2013 EBMH Associate Editor and chat facilitator, Holly Millward<\/p>\n<\/p>\n","protected":false},"excerpt":{"rendered":"